The pharmaceutical giant Pfizer has been fined a record £84m for charging the NHS too much for an anti-epilepsy drug.
Share Radio's Glen Goodman spoke with Angus Macculloch, Senior Lecturer of EU & UK Competition Law at Lancaster University for some clarification on the issue. Namely, how is it the Competitions and Markets Authority (CMA) determined Pfizer had been overcharging? Are public institutions like the NHS prone to being overcharged in this way?
